Head to head
Direct Meds vs MEDVi
What each one charges a month, which pharmacy each will name, and where each will treat you — read off their own sites, not their marketing.
Both sell compounded tirzepatide, where our ranking places Direct Meds at #10 and MEDVi at #105 — on the criteria we publish.
What each actually charges
A blank means that provider does not sell that compound at all. Prices are the real month-to-month figure, not a prepay or first-month rate.
| Compound | DM Direct Meds | ME MEDVi |
|---|---|---|
| Tirzepatide | $399/mo | $199/mo |
| Semaglutide | $297/mo | $166/mo |
| Sermorelin | $199/mo | Doesn't sell it |
| NAD+ | Not published | Doesn't sell it |
| Pharmacy named | Not disclosed | Not disclosed |
Direct Meds checked August 2026; MEDVi checked August 2026.
Who each one suits
Good fit if you've read FDA's warning letter and decided the marketing language it flagged doesn't change your decision.
The catch: FDA issued DirectMeds.com, Inc. a warning letter (MARCS-CMS #716822, September 9, 2025) over marketing that equated compounded semaglutide and tirzepatide with FDA-approved products: "Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not," flagging language including "Compounded semaglutide contains the same active ingredient as branded semaglutide." There is still no close-out letter, roughly eleven months on. Several peers here carry the same class of finding, and it is not disqualifying on its own — but it stays on the record here, with its date.
Good fit if you want one company selling both compounded tirzepatide and compounded semaglutide, with a headline price for each published directly on its site.
The catch: FDA issued MEDVi, LLC a warning letter (MARCS-CMS 721455, February 20, 2026, Center for Drug Evaluation and Research) — the same date, office, and "identifies '[name]' on the pictured label, suggesting [name] is the compounder when in fact it is not" template already documented here for a peer provider, addressed to MEDVi's own registered Delaware corporate address. Separately, outside investigative journalism (Futurism; Drug Discovery Trends) previously reported that MEDVi's advertising used fabricated physician names in ad creative; a live check of MEDVi's current core site (2026-08-03) found no named, invented physicians anywhere on its site today, though this was not an exhaustive sweep of every historical ad. Neither finding disqualifies MEDVi on its own, but both are on the record here.
Where each one will treat you
Direct Meds
There is no states-served list, and no exclusion list either. There is also no public Terms of Service page on the site, which is where a list like that usually lives.
MEDVi
No states-served list or exclusion list was found.
Ready to start with one?
Any paid placement here is marked Partner and listed first, as a disclosed commercial position — within that group, and separately within every other row, every provider is still ranked on the criteria printed on this page, never anything else
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.